Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2

Status

Terminated 4

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Myeloid 4Classical hematology 3Other hematologic neoplasm 1

Conditions

Myelodysplastic Syndromes 425Leukemia, Myeloid, Acute 351Leukemia 240Leukemia, Myelogenous, Chronic, BCR-ABL Positive 232Precursor Cell Lymphoblastic Leukemia-Lymphoma 211Myeloproliferative Disorders 161Lymphoma, Non-Hodgkin 156Hodgkin Disease 135Primary Myelofibrosis 129Leukemia, Lymphocytic, Chronic, B-Cell 129Multiple Myeloma 126Leukemia, Myelomonocytic, Chronic 118Lymphoma 106Leukemia, Myeloid, Chronic-Phase 78Lymphoma, Mantle-Cell 76Lymphoma, Follicular 71Congenital Abnormalities 69Blast Crisis 69Lymphoma, Large B-Cell, Diffuse 67Leukemia, Myeloid, Accelerated Phase 66Polycythemia Vera 64Lymphoma, B-Cell, Marginal Zone 64Burkitt Lymphoma 63Hematologic Neoplasms 53Anemia, Refractory, with Excess of Blasts 52Lymphoma, Large-Cell, Immunoblastic 51Neoplasms, Plasma Cell 47Myelodysplastic-Myeloproliferative Diseases 44Thrombocythemia, Essential 40Recurrence 40

Interventions

11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 2Surveys and Questionnaires 1ON 01910 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Has results × Splenomegaly × Myeloid × Clear all
NCT02055781 2021-11-18

PAC326

CTI BioPharma

Phase 3 Terminated
311 enrolled 12 charts
Classical hematologyMyeloid

Anemia, Bone Marrow Diseases, Hematologic Diseases, Hemorrhagic Disorders, Myeloproliferative Disorders, Polycythemia Vera, Splenomegaly, Thrombocythemia, Essential, Thrombocytopenia, Primary Myelofibrosis

NCT01773187 2020-09-29

Pacritinib Versus Best Available Therapy to Treat Myelofibrosis

CTI BioPharma

Phase 3 Terminated
327 enrolled 11 charts
Classical hematologyMyeloid

Anemia, Bone Marrow Diseases, Hematologic Diseases, Myeloproliferative Disorders, Polycythemia Vera, Splenomegaly, Thrombocythemia, Essential, Thrombocytopenia, Primary Myelofibrosis

NCT02730884 2020-08-07

Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia

M.D. Anderson Cancer Center

Phase 2 Terminated
3 enrolled 6 charts
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Leukemia, Splenomegaly, Primary Myelofibrosis

NCT02421354 2019-05-15

Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis

M.D. Anderson Cancer Center

Phase 2 Terminated
8 enrolled 7 charts
Myeloid

Hepatomegaly, Polycythemia Vera, Splenomegaly, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡